Matches in Wikidata for { <http://www.wikidata.org/entity/Q90833364> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- Q90833364 description "artículu científicu espublizáu en marzu de 2020" @default.
- Q90833364 description "im März 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90833364 description "scientific article published on 01 March 2020" @default.
- Q90833364 description "wetenschappelijk artikel" @default.
- Q90833364 description "наукова стаття, опублікована 1 березня 2020" @default.
- Q90833364 name "Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study" @default.
- Q90833364 name "Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study" @default.
- Q90833364 type Item @default.
- Q90833364 label "Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study" @default.
- Q90833364 label "Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study" @default.
- Q90833364 prefLabel "Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study" @default.
- Q90833364 prefLabel "Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study" @default.
- Q90833364 P1433 Q90833364-25B98F25-C53D-4F25-9F02-3DEEE089A093 @default.
- Q90833364 P1476 Q90833364-2171F3B9-78EC-49ED-9DEB-558741911395 @default.
- Q90833364 P2093 Q90833364-0AC3079E-BD22-4268-9211-A503C7FF28D3 @default.
- Q90833364 P2093 Q90833364-147A5CF3-5776-4C29-BABA-301B3A04DF12 @default.
- Q90833364 P2093 Q90833364-43D68A9B-B9DE-4A47-9E64-FBD1228EA7E2 @default.
- Q90833364 P2093 Q90833364-45EC17F1-F846-47D4-A178-501D7CF50050 @default.
- Q90833364 P2093 Q90833364-5FB31AAF-1D20-4BBD-B0E4-EDBE6778403C @default.
- Q90833364 P2093 Q90833364-A9029772-C712-4236-9585-678AEDEB7B1F @default.
- Q90833364 P2093 Q90833364-C731328A-FCDF-4D69-8BD3-D4BD0E8A952A @default.
- Q90833364 P2093 Q90833364-F355C257-5810-405F-9549-D062ED4C7F96 @default.
- Q90833364 P2093 Q90833364-F48D997C-2D7C-4676-B5BA-ED8EAC7EA46E @default.
- Q90833364 P275 Q90833364-772d0ce7-bbd1-4823-985a-09ee80190e2e @default.
- Q90833364 P2860 Q90833364-478C1AA8-6F76-42EB-BF9C-5CDF9F995560 @default.
- Q90833364 P2860 Q90833364-618791D2-0C61-4440-B54D-F85A63DABBAE @default.
- Q90833364 P31 Q90833364-4C18C704-52EB-4221-AC5C-A3226F8C06D1 @default.
- Q90833364 P356 Q90833364-EC77EA12-4F65-4D52-B514-44572C3BC132 @default.
- Q90833364 P433 Q90833364-A1F1351F-98D3-4A7F-97A8-D3D1BDBC8625 @default.
- Q90833364 P478 Q90833364-419316CD-EA2E-490F-84E2-41621FAA1933 @default.
- Q90833364 P50 Q90833364-6780FA6D-B50D-4F59-BE49-0177C66C2FCF @default.
- Q90833364 P50 Q90833364-990C4BC3-C169-41A8-A94B-89B5352DB45B @default.
- Q90833364 P50 Q90833364-9E418048-0302-470F-A082-651D9A4DBBE9 @default.
- Q90833364 P50 Q90833364-9FD7C693-A680-4C2C-B79E-30D509476B1B @default.
- Q90833364 P50 Q90833364-C43D5789-D21F-4E2B-AD35-64A96E4C0E6A @default.
- Q90833364 P577 Q90833364-5C08A91B-0E7F-49F6-B75B-5EBDC34A3A62 @default.
- Q90833364 P6216 Q90833364-338c3774-1ad4-40d8-991f-97eb1aa9afb3 @default.
- Q90833364 P698 Q90833364-8772F566-0523-46EF-AF8D-5D8784D80F9C @default.
- Q90833364 P921 Q90833364-8E2889C7-22D0-4A62-8828-E22015D27199 @default.
- Q90833364 P932 Q90833364-74F21D17-054F-41AA-B477-348F0D0ED88A @default.
- Q90833364 P356 JITC-2019-000166 @default.
- Q90833364 P698 32238469 @default.
- Q90833364 P1433 Q27725163 @default.
- Q90833364 P1476 "Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study" @default.
- Q90833364 P2093 "Anton Terwisscha van Scheltinga" @default.
- Q90833364 P2093 "Caroline van der Minne" @default.
- Q90833364 P2093 "Gerrit Jan Liefers" @default.
- Q90833364 P2093 "Inge Roozen" @default.
- Q90833364 P2093 "Linda de Bruin" @default.
- Q90833364 P2093 "Marij J Welters" @default.
- Q90833364 P2093 "Marten Visser" @default.
- Q90833364 P2093 "Pauline Meij" @default.
- Q90833364 P2093 "Saskia Santegoets" @default.
- Q90833364 P275 Q34179348 @default.
- Q90833364 P2860 Q29615679 @default.
- Q90833364 P2860 Q34555562 @default.
- Q90833364 P31 Q13442814 @default.
- Q90833364 P356 "10.1136/JITC-2019-000166" @default.
- Q90833364 P433 "1" @default.
- Q90833364 P478 "8" @default.
- Q90833364 P50 Q42825686 @default.
- Q90833364 P50 Q52982311 @default.
- Q90833364 P50 Q86638095 @default.
- Q90833364 P50 Q90315072 @default.
- Q90833364 P50 Q90833358 @default.
- Q90833364 P577 "2020-03-01T00:00:00Z" @default.
- Q90833364 P6216 Q50423863 @default.
- Q90833364 P698 "32238469" @default.
- Q90833364 P921 Q18975855 @default.
- Q90833364 P932 "7174065" @default.